| Home Colorectal Cancer Incidence in the first 3-4, and Beijing and Shanghai, according to the statistics, the incidence rate of 2.4 percent over the past decade to a rapid rise to become a serious hazard to the health of one of the malignant tumor. The treatment of colorectal cancer model is based on a comprehensive treatment of surgery, chemical drugs in colorectal cancer treatment is multidisciplinary and comprehensive treatment of an important component of the normative data to show that the chemical treatment of the joint to 5-year survival rate from 27.4% increased to 42.7%. 5-FU/CF chemotherapy is based on the current-based combination chemotherapy. However, the same disease stage, the same pathological type, the application of the same treatment and dose intensity, but different side effects or even lead to patients with diarrhea, infections, and even life-threatening, but because of the fear of side effects of treatment and give up. For these reasons, clinicians in the use force, the choice of a relatively low dose, it is difficult to achieve the greatest dose-effect relationship, the experience of side effects at the same time after the occurrence of the prevention and treatment greatly increased the financial burden of patients, clinical treatment due to side the choice of an urgent need to provide a clear reference to the individual indicators to guide the clinical use.The drug in colorectal cancer genomics research to develop more rapidly in recent years, especially with regard to 5-FU-related metabolic enzyme polymorphism as a hot cut. However, these studies focus on the present biochemical and cellular studies of Health, the level of the preliminary conclusions from the biochemical function of proteins confirmed the polymorphism of the difference between the influence of drugs. DPD and application of 5-FU chemotherapy toxicity is closely related, and we hope that the crowd of colorectal cancer by 5-FU and its derivatives and pharmacological role of metabolism key enzyme DPD distribution of single nucleotide polymorphisms of the study can guide the search for clinical genetic polymorphism of drug sites can find out the clinical chemotherapy of sensitive sites, through the promotion of clinical, in order to provide information on individual drugs and for the final of clinical genetic testing reagents basis in order to reduce the use of blindness drugs to reduce the burden on patients to improve the administration and efficacy of individual differences.In this study, Taqman MGB probe method dihydropyrimidine dehydrogenase single-nucleotide polymorphism analysis of its relationship with 5-FU chemotherapy-related side effects of drugs.In this study, patients with colorectal cancer EDT anticoagulant peripheral blood specimens of 60, the use of biotechnology companies in Dalian Bao Blood Genome DNA Extraction Kit extract genomic DNA, using ABI U.S. companies Taqman MGB probes for real-time fluorescence quantitative PCR amplification reactions and determination of the DPYD dihydropyrimidine dehydrogenase 14G1A, G2194A, T85C, G1156T, T464A sites, such as single nucleotide polymorphisms. Evaluation of dihydropyrimidine dehydrogenase in patients with single nucleotide polymorphisms and 5-FU-related side effects of drugs.Results: (1) dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms: 60 patients were not detected in 14G1A, G1156T polymorphism variation; G2194A polymorphism, the hybrid 6 cases (10.0%), 54 cases of wild-type (90.0%), no variation; T464A polymorphism, there are two cases of hybrid (3.3%), 58 cases of wild-type (96.7%), no variant; T85C polymorphism, we found mutations in two cases (3.3%), 8 cases of heterozygosity (13.3%), 50 cases of wild-type (83.4%). (2) T85C polymorphism followed by low incidence of side effects of mutant, heterozygous and wild-type, the difference was statistically significant (P <0.05); T464A, G2194A hybrid side effects higher than wild-type, the difference was statistically significant (P <0.05).Conclusion: The combination of domestic literature and the experimental results, the current colorectal cancer has not yet been detected in patients with dihydropyrimidine dehydrogenase 14G1A, G1156T polymorphism variation, yet they can not be applied to individual treatment; detected G2194A, T464A, T85C polymorphism, there are hybrid, wild-type, variant mutation; and low incidence of side effects are followed mutant, heterozygous and wild-type. The desirability of these sites to guide individual treatment. Dihydropyrimidine dehydrogenase gene single nucleotide polymorphism detection in predicting 5-FU toxicity of chemotherapy has some guiding significance for the individual colorectal cancer provides a theoretical basis for treatment. |
PDF Full Text Request